An in-vitro study is conducted outside a living organism — in a dish or test tube, on cells or isolated biological material. An in-vivo study is conducted within a living organism. Preclinical research covers all study before human testing begins, generally including both in-vitro work and in-vivo animal studies. Clinical research is study conducted in humans; a clinical trial is a structured clinical research study with a defined protocol, typically to test safety and effectiveness.
Human clinical trials are generally organized into Phase I (a small group, primarily testing safety and dosing), Phase II (a larger group, testing effectiveness and further safety), and Phase III (a still larger, often multi-site group, confirming effectiveness and monitoring for less common effects, typically the phase whose results support a regulatory approval decision). A randomized controlled trial (RCT) is a study design where participants are randomly assigned to a treatment or a comparison group specifically to reduce bias in the result.
Peer review is the process of a scientific paper being evaluated by other experts in the field before publication — a quality check, not a guarantee of correctness. “Statistically significant” means an observed result is unlikely to be due to chance alone, under the assumptions of the statistical test used; it does not by itself mean the effect is large or meaningful in practice, which is what “clinical significance” separately asks.
Preclinical findings — especially from cell or animal studies — can differ from human outcomes because biological systems differ across species, doses and exposure routes differ, and a mechanism that works in a simplified system does not always translate cleanly into a whole organism. For the same reason, a compound interacting with a receptor in a way that looks promising mechanistically does not, on its own, demonstrate a clinical benefit — that requires the later stages of clinical research to actually show it.